The considerable effects of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) gene on the low-density lipoprotein receptor (LDLR) and ultimately the plasma level of LDL-cholesterol are suggested as a good candidate for the therapy of CHD [16]. The gene discussed is LDLR; the disease is coronary artery disorder.